ReviewFEBS letters2010
Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers.
Review in FEBS letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.Current oncology reports · 2026Review
- Decoding the Sphingolipid Landscape of Clear Cell Renal Cell Carcinoma: A Single-Cell-Guided Prognostic Model Built With 101 Machine Learning.Human mutation · 2026Article
- Preclinical Evaluation of a Near-Infrared Labelled Antibody Targeting the Tumour Associated Xenoantigen N-Glycolyl-Neuraminic Acid GM3 Ganglioside.Molecular imaging and biology · 2025Article
- Hypoxic Status in COPD and ARDS Patients: Impact on Lipid Signature.International journal of molecular sciences · 2025Article
- The Role of Non-Human Sialic Acid Neu5Gc-Containing Glycoconjugates in Human Tumors: A Review of Clinical and Experimental Evidence.Biomolecules · 2025Review
- Secretion of Sphinganine by Drug-Induced Cancer Cells and Modified Mimetic Sphinganine (MMS) as c-Src Kinase Inhibitor.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Biology of GD2 ganglioside: implications for cancer immunotherapy.Frontiers in pharmacology · 2023Review
- Abnormal expression of HADH, an enzyme of fatty acid oxidation, affects tumor development and prognosis (Review).Molecular medicine reports · 2022Review
- Glycosphingolipid-Glycan Signatures of Acute Myeloid Leukemia Cell Lines Reflect Hematopoietic Differentiation.Journal of proteome research · 2022Article
- Article
- Review
- Preliminary Analysis of the Glycolipid Profile in Secondary Brain Tumors.BioMed research international · 2022Article
- Surface expression of the immunotherapeutic target GCancer reports (Hoboken, N.J.) · 2021Article
- Cancer stem cells and ceramide signaling: the cutting edges of immunotherapy.Molecular biology reports · 2020Review
- Comprehensive Profiling of Surface Gangliosides Extracted from Various Cell Lines by LC-MS/MS.Cells · 2019Article
- Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017Review
- Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.Gene therapy · 2015Article
- Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.Cellular and molecular life sciences : CMLS · 2015Review
- Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells.PloS one · 2015Article
- Molecular recognition of gangliosides and their potential for cancer immunotherapies.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Uncontrolled growth of malignant cells produces hypoxic regions in locally advanced tumors. Recently we showed that tumor hypoxia-induced transcription of multiple genes involved in glycan synthesis, leading to expression of useful glycolipid tumor markers, such as gangliosides having N-glycolyl sialic acid. Our subsequent studies indicated that the ceramide portion of glycolipids, as well as their glycan moiety, was also significantly affected by hypoxia. Tumor hypoxia-induced marked accumulation of sphinganine (dihydrosphingosine) long-chain base, and significant reduction of unsaturated very long-chain fatty acids in the ceramide moiety. Mass-spectrometry, which yields information on both glycan- and ceramide moieties, is expected to be clinically useful in detecting such distinct molecular species of cancer-associated glycolipids having combined alteration in both glycan- and ceramide moieties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.